ELVHealthcare · Healthcare PlansThe 22 Wall Street analysts covering Elevance Health, Inc. hold a median 12-month price target of $457 — +14.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Elevance Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (89): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (37): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ELV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +14.1% from it.
Of the 20 most recent actions, 8 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 July 2026 | Leerink Partners | Maintains | Market Perform | $364 → $395 |
| 16 July 2026 | Baird | Maintains | Neutral | $331 → $393 |
| 16 July 2026 | Barclays | Maintains | Overweight | $480 → $457 |
| 16 July 2026 | Guggenheim | Maintains | Buy | $399 → $455 |
| 16 July 2026 | RBC Capital | Maintains | Sector Perform | $439 → $424 |
| 16 July 2026 | Wells Fargo | Maintains | Overweight | $492 → $473 |
| 14 July 2026 | TD Cowen | Maintains | Buy | $400 → $465 |
| 14 July 2026 | Truist Securities | Maintains | Buy | $450 → $475 |
| 13 July 2026 | Wells Fargo | Maintains | Overweight | $391 → $492 |
| 9 July 2026 | RBC Capital | Maintains | Sector Perform | — |
| 9 July 2026 | RBC Capital | Maintains | Sector Perform | $358 → $439 |
| 7 July 2026 | Cantor Fitzgerald | Maintains | Overweight | $400 → $450 |
| 7 July 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 2 July 2026 | Bernstein | Maintains | Outperform | — |
| 8 June 2026 | JP Morgan | Maintains | Overweight | — |
| 8 June 2026 | Mizuho | Maintains | Outperform | — |
| 4 June 2026 | B of A Securities | Maintains | Buy | — |
| 4 June 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 1 June 2026 | Truist Securities | Maintains | Buy | — |
| 26 May 2026 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELV appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 42% of US stocks
Cheaper than 85% of US stocks
Cheaper than 48% of US stocks
Cheaper than 40% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 54% of US stocks
Higher than 53% of US stocks
Higher than 66% of US stocks
Higher than 70% of US stocks
Higher than 40% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Elevance Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Elevance Health (ELV) reported earnings 30 days ago, and its stock has risen 6.8% since that report. The article questions whether the stock can continue its upward momentum.
Why it matters — Investors watching ELV would care about whether the post-earnings stock gain signals continued growth or a peak in the share price.
Elevance Health announced enhancements to its connected cancer care model, aimed at providing earlier support, personalized care navigation, and more coordinated care for consumers throughout their cancer journeys.
Why it matters — This initiative could strengthen Elevance's value proposition in the healthcare market by addressing a significant, emotionally and logistically complex area of patient care.
The Oakmark U.S. Large Value Strategy's Q2 2026 portfolio review discusses Delta Air Lines as a contributor despite fuel price headwinds from the Iran War, a decline in Intercontinental Exchange stock price due to AI disruption concerns, and a new position in Equitable Holdings. No mention of Elevance Health (ELV) appears in the report.
Why it matters — ELV watchers would note that the Oakmark strategy review contains no information directly relevant to Elevance Health, as the discussion focuses on other portfolio holdings.
The GreensKeeper Value Fund's Q2 2026 portfolio update does not mention Elevance Health, Inc. The fund noted ICON plc as its top performer and Intercontinental Exchange as its largest detractor, with no major portfolio changes made during the quarter.
Why it matters — ELV watchers would note that the fund's update contains no new information or positioning changes regarding Elevance Health.
The article discusses Seth Klarman's Baupost Group's five largest common-stock positions as disclosed in a 13F filing for the period ending March 31, 2026, filed on May 14, 2026.
Why it matters — For ELV watchers, this matters because major institutional investors' top holdings can influence market perception and signal conviction in certain sectors or companies.
The 22 Wall Street analysts covering Elevance Health, Inc. have a median 12-month price target of $457, with estimates ranging from $393 to $492. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 22 analysts covering Elevance Health, Inc., 15 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elevance Health, Inc. 66 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Elevance Health, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (89 of 100).
No one can know that. What the data says: the median 12-month target from 22 analysts implies +14.1% from the last close, and Ticker Nerd's factor model ranks Elevance Health, Inc. 66 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Elevance Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $393 to $492 over the next 12 months.
Elevance Health, Inc. returned +32.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Elevance Health, Inc. is a diversified health company headquartered in Indianapolis, Indiana.
The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Elevance Health (ELV) Up 6.8% Since Last Earnings Report: Can It Continue?". Elevance Health (ELV) reported earnings 30 days ago, and its stock has risen 6.8% since that report. The article questions whether the stock can continue its upward momentum.
Elevance Health, Inc. is a diversified health company headquartered in Indianapolis, Indiana. The company focuses on supporting health at every life stage by integrating medical, pharmacy, behavioral, and complex-care services. Elevance Health operates through several key segments. Its Health Benefits segment provides a broad range of commercial, Medicaid, Medicare, and specialty health plans to individuals, employers, and government programs. Through CarelonRx, it offers pharmacy benefit management solutions, including prescription management and related pharmacy services. Carelon Services delivers care management, analytics, and other clinical and administrative services aimed at coordinating and improving care quality. Together, these businesses enable Elevance Health to serve as a major player in the U.S. healthcare system, connecting health plans, care providers, and consumers to streamline access to care and support better health outcomes across diverse populations.
CEO Ms. Gail Koziara Boudreaux · 96,129 employees · United States · https://www.elevancehealth.com